➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
McKesson
Dow
Johnson and Johnson

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,772,209

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,772,209 protect, and when does it expire?

Patent 7,772,209 protects PEMFEXY and ALIMTA and is included in two NDAs.

Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 7,772,209
Title:Antifolate combination therapies
Abstract:A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s): Niyikiza; Clet (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/776,329
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,772,209
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,772,209

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eagle Pharms PEMFEXY pemetrexed SOLUTION;INTRAVENOUS 209472-001 Feb 8, 2020 RX Yes Yes   Start Trial   Start Trial USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA   Start Trial
Eagle Pharms PEMFEXY pemetrexed SOLUTION;INTRAVENOUS 209472-001 Feb 8, 2020 RX Yes Yes   Start Trial   Start Trial USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Harvard Business School
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.